Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 16,190 shares of the business’s stock in a transaction that occurred on Monday, September 13th. The stock was sold at an average price of $20.00, for a total value of $323,800.00. Following the sale, the executive vice president now owns 15,000 shares of the company’s stock, valued at $300,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Annexon stock opened at $22.04 on Friday. Annexon, Inc. has a 52 week low of $15.52 and a 52 week high of $38.01. The business’s fifty day simple moving average is $19.86 and its 200-day simple moving average is $22.72. The firm has a market cap of $844.84 million, a PE ratio of -7.65 and a beta of 1.39.
Annexon (NASDAQ:ANNX) last posted its quarterly earnings data on Sunday, August 15th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.13). On average, research analysts expect that Annexon, Inc. will post -3 earnings per share for the current year.
Separately, Zacks Investment Research lowered Annexon from a “hold” rating to a “sell” rating in a research note on Friday, August 20th.
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
Featured Article: Investing strategies using the yield curve
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.